[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100424991":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":54,"collaborators":11,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":11,"enrollmentInfo":65,"targetDuration":11,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":39,"whyStopped":11,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"British Columbia Cancer Agency","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Targeted therapy","EXPERIMENTAL",null,[13,14],"Behavioral: QOL","Diagnostic Test: CT imaging",[16,21],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":11},"BEHAVIORAL","QOL","QOL assessments using the ESAS, CPC, EQ5D every 4-8 weeks +\u002F- 2 weeks",[9],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":11},"DIAGNOSTIC_TEST","CT imaging","CT radiographic imaging every 12 weeks +\u002F- 2 weeks",[9],[27],{"name":28,"affiliation":29,"role":30},"Cheryl Ho, MD","BC Cancer","PRINCIPAL_INVESTIGATOR",[32],{"name":33,"role":34,"phone":35,"phoneExt":11,"email":36},"Samantha Pollard, PhD","CONTACT","604-675-8000","spollard@bccrc.ca",[38],{"facility":29,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"RECRUITING","Vancouver","British Columbia","V5Z4E6","Canada","CA",{"type":46,"coordinates":47},"Point",[48,49],-123.11934,49.24966,{"lat":49,"lon":48},[52],{"name":28,"role":34,"phone":53,"phoneExt":11,"email":11},"604-877-6000",{"type":55,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100424991","precision-oncology-evidence-development-in-cancer-treatment---clinical-predictc-100424991",false,"NCT04814095","PRecision Oncology Evidence Development in Cancer Treatment - Clinical: PREDiCTc","PREDiCTc","Inclusion Criteria:\n\n* Subject age greater than or equal to 18 years at the time of signature of informed consent.\n* Subjects with an incurable malignancy who have been identified to have a rare cancer or rare molecular aberration who is currently receiving Health Canada approved targeted therapy that is not nationally funded\n* ECOG 0-2\n* Life expectancy of at least 12 weeks\n* Adequate hematologic and end organ function for drug treatment per the clinician's assessment\n* Asymptomatic or treated brain metastases permitted\n* Ability to give informed consent for the study procedures defined in this protocol.\n\nExclusion Criteria:\n\n* Treatment with any approved or investigational agent or participation in another clinical trial with therapeutic intent within 14 days prior to enrollment.\n* Inability to complete quality of life questionnaires\n* Subjects who are felt by the treating clinician to be unfit to proceed with this protocol.","ALL","18 Years",{"count":66,"type":67},30,"ESTIMATED","INTERVENTIONAL",[70],"NA","This pilot clinical trial aims to assess the real world quality of life and survival of patients treated with targeted therapy that has preliminary evidence of efficacy in subjects with advanced rare cancers or cancer harbouring rare molecular aberrations. The treatment has been granted conditional or full approved by Health Canada (HC) as effective and safe. Due to the rarity of the cancer or molecular aberration the uncertainty level of the health technology assessment (HTA) by the pan Canadian Oncology Review (pCODR) was too high for consideration of funding or it was not submitted for consideration. Consequently, the goal of this study is to generate real world evidence to support HTA decision making throughout the life cycle of the product.",[73],"Cancer",[75,76,77,78],"targeted therapy","health technology assessment","real world evidence","quality of life","2025-09-22",{"date":81,"type":82},"2025-09-25","ACTUAL",{"date":84,"type":82},"2021-06-30",{"date":86,"type":67},"2028-05-01",{"name":5,"class":6},1]